Welcome to our dedicated page for Biodexa Pharmaceuticals news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals stock.
Biodexa Pharmaceuticals plc reports news on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs. The company’s programs include eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240, a molecular glue candidate for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes.
Recurring developments cover clinical development, regulatory and trial authorizations, manufacturing and access partnerships, licensing, annual results, financing activity, ADR program matters and patient-advocacy initiatives. Biodexa’s American depositary shares trade under BDRX, while company updates may also describe ordinary-share and ADR mechanics for the U.K. issuer.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has issued a shareholder letter outlining proposals to reorganize its share capital at the June 17, 2026 AGM.
The plan includes a 10,000:1 reverse split of 373,056,808,922 ordinary shares into 37,305,681, creation of E deferred shares, and changing the ordinary share/ADS ratio from 500,000:1 to 50:1, keeping approximately 746,113 ADSs and shareholder rights and ownership percentages unchanged.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced a partnership with Syngene to manufacture GMP clinical trial supplies of MTX240, covering both the active pharmaceutical ingredient and dosage form.
According to the company, Syngene previously manufactured tolimidone on time and on budget and, following Biodexa's MTX240 license from Otsuka in early February, designed a GMP program within a few weeks.
Biodexa (Nasdaq: BDRX) and Tanner Pharma Group launched a global Early Access / Named Patient Program for eRapa to treat Familial Adenomatous Polyposis (FAP) on March 31, 2026. The program enables clinicians to prescribe investigational oral rapamycin capsules outside clinical trials where local regulations permit.
The initiative aims to expand access, provide compliant, controlled supply in countries where eRapa is not available, and collect Real World Data (RWD) to improve understanding of FAP and patient experience. Access depends on patient eligibility, local laws, and funding availability.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced audited preliminary results for the year ended 31 December 2025. The company is a clinical-stage biopharmaceutical focused on treatments and prevention for gastrointestinal cancers. Contact details provided include CEO Stephen Stamp and CFO Fiona Sharp.
The announcement confirms the availability of audited preliminary results and directs stakeholders to Biodexa for further information.
Biodexa (Nasdaq: BDRX) has launched a global Early Access Program for its investigational medicine eRapa to treat Familial Adenomatous Polyposis (FAP) patients via a strategic partnership with Tanner Pharma Group.
The program enables clinicians worldwide to prescribe eRapa outside clinical trials, subject to local laws and funding, and Biodexa will collect Real World Data to better understand FAP patient experiences.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an ADR ratio change from 1 ADR = 100,000 ordinary shares to 1 ADR = 500,000 ordinary shares, effective on or about April 6, 2026. ADR holders must surrender five old ADRs for one new ADR (New CUSIP: 59564R872).
The change will operate as a one-for-five reverse ADR split for ADRs only; ordinary shares are not affected. The depositary, JP Morgan Chase Bank, N.A., will manage exchanges and sell any aggregate fractional interests, distributing net proceeds. The Company said the change aims to comply with Nasdaq's $1.00 minimum bid requirement but gave no assurance it will achieve that outcome.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an initial financial grant supporting the launch of Life's a Polyp Foundation, the first U.S. patient advocacy group focused exclusively on Familial Adenomatous Polyposis (FAP).
Biodexa highlighted its lead program eRapa, an encapsulated rapamycin in the registrational Phase 3 Serenta trial with >20% enrollment and FDA Fast Track designation, and said the grant aims to boost patient resources, community support, and awareness for FAP patients and families.
Biodexa (NASDAQ:BDRX) licensed MTX240, a Phase 1–ready molecular glue for gastrointestinal stromal tumors (GIST), from Otsuka on February 19, 2026.
MTX240 showed dose-dependent preclinical efficacy in TKI-resistant and non-resistant GIST models, is eligible for US/EU Orphan Drug exclusivity, has composition‑of‑matter patents through 2037, and a Phase 1b/2a trial is planned by year-end.
Biodexa (Nasdaq: BDRX) closed an exclusive license with Otsuka for OPB-171775, a Phase 1–ready molecular glue intended for treatment of gastrointestinal stromal tumours (GIST). Biodexa will develop the asset as MTX240, citing activity in TKI‑resistant PDX models and potential use in additional indications. The program aligns with Biodexa's GI/oncology pipeline alongside its Phase 3 eRapa program in Familial Adenomatous Polyposis.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced on January 5, 2026 the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary and her election to the Board of Directors, effective immediately.
Ms Sharp joined Biodexa as Group Financial Controller in December 2019 and has assumed many CFO responsibilities during her tenure. Her prior roles include Assistant Director of Finance at Hywel Dda University Health Board (over 10,000 staff; budget ~£800 million) and senior finance roles at Chime Communications Group (revenues ~£570 million) from 1999 until early 2018. Stephen Stamp will relinquish his CFO and Company Secretary roles but will remain as Chief Executive Officer.